Compare ArcelorMittal SA (MT) vs Organon & Co. Common Stock (OGN) Price & Performance

ArcelorMittal (MT) trades at $62.49, down 0.73% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with declining revenue from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent Ukraine plant impairments and missile strikes create operational headwinds, while analyst consensus remains positive with a $74.33 price target representing 19% upside potential.

MT presents a value opportunity with attractive valuation multiples (P/S 0.77, P/B 0.87) and strong cash flow generation, but faces significant geopolitical risks and declining revenue trends. The company's strategic shift toward regional operations and shareholder returns supports long-term potential, though near-term volatility from European demand fluctuations and Ukraine impairments requires careful risk management.

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.